Athenex Inc
F:2MT
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
This alert will be permanently deleted.
Athenex Inc
Inventory
Athenex Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Athenex Inc
F:2MT
|
Inventory
$42.7m
|
CAGR 3-Years
9%
|
CAGR 5-Years
21%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Inventory
$4.9B
|
CAGR 3-Years
16%
|
CAGR 5-Years
7%
|
CAGR 10-Years
10%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Inventory
$4.4B
|
CAGR 3-Years
44%
|
CAGR 5-Years
34%
|
CAGR 10-Years
8%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Inventory
$6.3B
|
CAGR 3-Years
10%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Inventory
$1.6B
|
CAGR 3-Years
61%
|
CAGR 5-Years
46%
|
CAGR 10-Years
42%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Inventory
$2.4B
|
CAGR 3-Years
0%
|
CAGR 5-Years
6%
|
CAGR 10-Years
29%
|
|
Athenex Inc
Glance View
Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 652 full-time employees. The company went IPO on 2017-06-14. The Company’s platforms include Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Oncology Innovation Platform is engaged in research and development of its drugs. Global Supply Chain Platform is engaged in supplying active pharmaceutical ingredient to clinical and commercial efforts. Commercial Platform includes specialty pharmaceuticals business, and manufacture and marketing of products. The Company’s product pipeline includes Orascovery, Src Kinase Inhibition, Cell Therapy and Arginine Deprivation Therapy. Its lead product candidate Orascovery platform technology is based on the oral P-gp pump inhibitor molecule, encequidar. The Src Kinase inhibition platform technology is based on small molecule compounds including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization.
See Also
What is Athenex Inc's Inventory?
Inventory
42.7m
USD
Based on the financial report for Dec 31, 2022, Athenex Inc's Inventory amounts to 42.7m USD.
What is Athenex Inc's Inventory growth rate?
Inventory CAGR 5Y
21%
Over the last year, the Inventory growth was 23%. The average annual Inventory growth rates for Athenex Inc have been 9% over the past three years , 21% over the past five years .
